Skip to main content

Table 3 Median TTP, HR and 95%CIs between combination therapy group and TACE alone group

From: Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Authors (year) Combination group (95% CI)/months TACE alone group (95% CI)/months HR (95% CI)
Kudo et al. (2011) [15] 5.4(3.8–7.2) 3.7 (3.5–4.0) 0.87(0.70–1.09)
Sansonno et al.(2012) [44] 9.2 4.9 2.5(1.66–7.56)
Lencioni et al. (2012) [10] 5.6 5.5 0.797 (0.588–1.08)
Bai et al. (2013) [46] 6.3 4.3 0.6 (0.422–0.853)
Muhammad et al. (2013) [47] NA NA 0.93 (0.45–1.89)
Huang et al. (2013) [48] 5.4 3.7 0.99 (0.67–1.47)
Hu et al. (2014) [14] 2.6 1.9 0.62 (0.47–0.82)
Ohki et al. (2015) [6] 6.3 3.5 0.38 (0.22–0.63)
Yao et al. (2015) [12] 10.2 6.7 0.403 (0.251–0.646)
Zhang et al. (2016) [49] 4.9 (3.7–6.0) 2.4 (1.3–3.4) NA
  1. Abbreviations: TTP time to progression, HR hazard ratio, 95%CIs 95% confidence intervals, NA not available
\